Evidence map›Paper›PMID 41514589›Full record

ArticleCancers2025

Age and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance.

Tiago Pina-Cabral, José Pereira, João Paulo-Fernandes, Márcia Silva, Mário Fontes-Sousa, Mariana Anacleto, Soraia Lobo-Martins, Ana Mirco, Helena Miranda, Ana Martins and 1 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tiago Pina-CabralUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.ORCID 0000-0003-4482-3909
José PereiraUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.ORCID 0009-0001-5534-2636
João Paulo-FernandesUnidade de Farmacovigilancia, Direção de Gestão do Risco de Medicamentos, INFARMED-Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., 1749-004 Lisbon, Portugal.ORCID 0000-0002-2030-0057
Márcia SilvaUnidade de Farmacovigilancia, Direção de Gestão do Risco de Medicamentos, INFARMED-Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., 1749-004 Lisbon, Portugal.
Mário Fontes-SousaUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.ORCID 0000-0003-0337-3251
Mariana AnacletoUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.
Soraia Lobo-MartinsUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.ORCID 0000-0001-5847-7192
Ana MircoUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.ORCID 0000-0001-9668-7561
Helena MirandaUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.
Ana MartinsUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.ORCID 0009-0002-6633-1892
Patrícia CavacoUnidade Local de Saúde de Lisboa Ocidental, 1449-005 Lisbon, Portugal.ORCID 0000-0002-3404-6782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CTLA-4elderlyimmune checkpoint inhibitorsimmune-related adverse eventspharmacovigilancePortugalreal-world evidence

Identifiers

PMID41514589
PMCPMC12784953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.